Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1471-2407

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer ; volume:13 ; number:1 ; day:23 ; month:9 ; year:2013 ; pages:1-8 ; date:12.2013
BMC cancer ; 13, Heft 1 (23.9.2013), 1-8, 12.2013

Creator: Hwang, Jun-Eul

Contributor: Hong, Ji-Yun
Kim, Karham
Kim, Seung-Hun
Choi, Won-Young
Kim, Min-Jee
Jung, Sung-Hoon
Shim, Hyun-Jeong
Bae, Woo-Kyun
Hwang, Eu-Chang
Lee, Kyung-Hwa
Lee, Jae-Hyuk
Cho, Sang-Hee
Chung, Ik-Joo
SpringerLink (Online service)

DOI: 10.1186/1471-2407-13-431

URN: urn:nbn:de:1111-2016030410868

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:31 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Hwang, Jun-Eul
Hong, Ji-Yun
Kim, Karham
Kim, Seung-Hun
Choi, Won-Young
Kim, Min-Jee
Jung, Sung-Hoon
Shim, Hyun-Jeong
Bae, Woo-Kyun
Hwang, Eu-Chang
Lee, Kyung-Hwa
Lee, Jae-Hyuk
Cho, Sang-Hee
Chung, Ik-Joo
SpringerLink (Online service)

Other Objects (12)

Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?

Changes in neutrophile-to-lymphocyte ratio as predictive and prognostic biomarker in metastatic prostate cancer treated with taxane-based chemotherapy

Upfront taxane could be superior to pegylated liposomal doxorubicin (PLD): a retrospective real-world analysis of treatment sequence taxane–PLD versus PLD–taxane in patients with metastatic breast cancer

Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study

Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy

Taxane/gemcitabine-containing chemotherapy plus locoregional IMRT for patients with de novo metastatic nasopharyngeal carcinoma: the treatment outcomes and prognostic factors analysis

Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer

In vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovarian cancer

Taxane Combination Chemotherapy in Breast Cancer: Experience from a Tertiary Cancer Centre in India

A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma

Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine

First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048

Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?

Changes in neutrophile-to-lymphocyte ratio as predictive and prognostic biomarker in metastatic prostate cancer treated with taxane-based chemotherapy

Upfront taxane could be superior to pegylated liposomal doxorubicin (PLD): a retrospective real-world analysis of treatment sequence taxane–PLD versus PLD–taxane in patients with metastatic breast cancer

Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study

Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy

Taxane/gemcitabine-containing chemotherapy plus locoregional IMRT for patients with de novo metastatic nasopharyngeal carcinoma: the treatment outcomes and prognostic factors analysis

Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer

In vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovarian cancer

Taxane Combination Chemotherapy in Breast Cancer: Experience from a Tertiary Cancer Centre in India

A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma

Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine

First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048

Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?

Changes in neutrophile-to-lymphocyte ratio as predictive and prognostic biomarker in metastatic prostate cancer treated with taxane-based chemotherapy

Upfront taxane could be superior to pegylated liposomal doxorubicin (PLD): a retrospective real-world analysis of treatment sequence taxane–PLD versus PLD–taxane in patients with metastatic breast cancer

Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study

Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy

Taxane/gemcitabine-containing chemotherapy plus locoregional IMRT for patients with de novo metastatic nasopharyngeal carcinoma: the treatment outcomes and prognostic factors analysis

Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer

In vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovarian cancer

Taxane Combination Chemotherapy in Breast Cancer: Experience from a Tertiary Cancer Centre in India

A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma

Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine

First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?

Changes in neutrophile-to-lymphocyte ratio as predictive and prognostic biomarker in metastatic prostate cancer treated with taxane-based chemotherapy

Upfront taxane could be superior to pegylated liposomal doxorubicin (PLD): a retrospective real-world analysis of treatment sequence taxane–PLD versus PLD–taxane in patients with metastatic breast cancer

Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study

Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy

Taxane/gemcitabine-containing chemotherapy plus locoregional IMRT for patients with de novo metastatic nasopharyngeal carcinoma: the treatment outcomes and prognostic factors analysis

Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer

In vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovarian cancer

Taxane Combination Chemotherapy in Breast Cancer: Experience from a Tertiary Cancer Centre in India

A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma

Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine

First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048

Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?

Changes in neutrophile-to-lymphocyte ratio as predictive and prognostic biomarker in metastatic prostate cancer treated with taxane-based chemotherapy

Upfront taxane could be superior to pegylated liposomal doxorubicin (PLD): a retrospective real-world analysis of treatment sequence taxane–PLD versus PLD–taxane in patients with metastatic breast cancer

Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study

Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy

Taxane/gemcitabine-containing chemotherapy plus locoregional IMRT for patients with de novo metastatic nasopharyngeal carcinoma: the treatment outcomes and prognostic factors analysis

Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer

In vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovarian cancer

Taxane Combination Chemotherapy in Breast Cancer: Experience from a Tertiary Cancer Centre in India

A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma

Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine

First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048

Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?

Changes in neutrophile-to-lymphocyte ratio as predictive and prognostic biomarker in metastatic prostate cancer treated with taxane-based chemotherapy

Upfront taxane could be superior to pegylated liposomal doxorubicin (PLD): a retrospective real-world analysis of treatment sequence taxane–PLD versus PLD–taxane in patients with metastatic breast cancer

Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study

Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy

Taxane/gemcitabine-containing chemotherapy plus locoregional IMRT for patients with de novo metastatic nasopharyngeal carcinoma: the treatment outcomes and prognostic factors analysis

Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer

In vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovarian cancer

Taxane Combination Chemotherapy in Breast Cancer: Experience from a Tertiary Cancer Centre in India

A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma

Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine

First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048

Related objects

Reset password